On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...

Bayer vice president Luiz Barberini explains how the German giant’s cooperation with suppliers fosters long-term trial ...

PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing correction in a Phase I trial.

As China's biotech sector continues to buzz with innovation, the country is rapidly integrating into the global clinical ...

MediciNova has completed full patient enrolment in the COMBAT-ALS Phase IIb/III clinical trial of MN-166 (ibudilast) as a ...

Belite Bio has concluded the final participant visit in its Phase III DRAGON study, which is focused on assessing the ...

Kairos Pharma has reported encouraging interim efficacy data from its Phase II study of ENV105 in individuals with mCRPC.

Datavant has partnered with life sciences commercialisation firm Indegene to enhance recruitment of subjects for clinical ...

The main concerns about tariffs that businesses have are higher input costs and uncertainty in long-term planning.

Trially has raised $4.7m in a seed funding round and introduced its agentic AI solution, Margo, designed to increase study ...

Johnson & Johnson said the combination was investigated in 49 patients with newly diagnosed multiple myeloma. Image credit: PixelBiss / Shutterstock.com Johnson & Johnson’s (J&J’s) multiple myeloma ...

Despite missing the primary endpoint, aTyr Pharma still sees a future for the drug as it plans further FDA discussions.